joining us now for a cnbc exclusive interview tilray ceo brendan kennedy.much for joining us stock is popping after hours give us the highlights in your view of the quarter. >> thanks, sara and wilf we're very pleased with our q1 results which include the first quarter of canadian adult use. revenue up 195% year over year to 23 million u.s. dollars, which shows the long-term opportunity we see not only in canada but other countries around the world >> when do you see the balance with those other countries around the world ramping up as well to the same extent you've seen in canada already >> i think if you look at our results you'll see increased revenue from international sales and we expect to see that continue throughout this year. germany is an important emerging market two weeks ago i was at our facility in portugal for a ribbon cutting and production at that facility continues to ramp. we expect to begin exporting from portugal to germany and other countries in the eu. we'll see in the second half of this year. >> you made a number of acquisitions ove

okay in the first few months after tilray's ipo, brendan kennedy was very, very, very, very, very, veryitive about the whole industry but in retrospect, maybe two positive how how medical cannabis could be a billion dollar business but then they would have to hedge the cannabis space the implication being it will have to make investments because of a threat he painted a very good long-term bullish picture. i buy into the picture canopy got $4 billion from constellation. the closest tilray has come, they got a research partner with busch where both companies have kicked in $50 million. it's pretty funny. listen to what kennedy told us you get the point. >> our intent is to build a company that dominates part of this $150 billion industry i think you'll see multiple billion companies. well don't want to partner with abi. we want to build abi >> yeah, see, i guess that's not really panning out as expected when i asked kennedy about cautious excellentary from other players in the industry, he told us that tilray would be able to defend their high price points until it reported last week, th

on its investments in a competitive market which weighed on the bottom line on the call, ceo, brendan kennedy said the company is seeing high demand in the canadian market and is spending more than $32 million to expand canadian production cast and tilray is investing in international markets and it opened up a medical cannabis operation in portugal. it also just closed its acquisition of harvest and tilray is looking for new partnerships and it has deals with inbev and tilray is eyeing a number of industries for future partnerships. >> we've mentioned pharmaceuticals. we've mentioned alcohol. we're starting to see tobacco companies enter the industry i think retail is the next year where lots of retailers throughout the united states are looking to have cannabis products or products derived from cannabis, primarily cbd on their shelves and we hope to have our products on their shelves in the second half of this year. >> another key metric from their earnings, total telegraph soared twofold to more than 3,000, but the average selling net price per gram decreased to $5.50 compared to 5.94 a ye